NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Price Target & More

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals announced that its Board of Directors has approved a stock buyback program on Wednesday, March 28th 2018, which permits the company to buyback $7,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 2.7% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board believes its shares are undervalued.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) posted its quarterly earnings data on Wednesday, May, 2nd. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.08. The business had revenue of $33.29 million for the quarter, compared to analysts' expectations of $29.60 million. Avadel Pharmaceuticals had a negative return on equity of 13.95% and a net margin of 18.96%. View Avadel Pharmaceuticals' Earnings History.

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Avadel Pharmaceuticals.

3 brokers have issued 12-month price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $14.00 to $30.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $22.6667 in the next twelve months. View Analyst Ratings for Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include Esperion Therapeutics (ESPR), Eagle Pharmaceuticals (EGRX), TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Endocyte (ECYT), Flexion Therapeutics (FLXN), Reata Pharmaceuticals (RETA), Dynavax Technologies (DVAX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), CytomX Therapeutics (CTMX), MacroGenics (MGNX), Amarin (AMRN), Omeros (OMER) and Karyopharm Therapeutics (KPTI).

News coverage about AVDL stock has trended somewhat positive recently, according to Accern. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Avadel Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the company an impact score of 46.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Avadel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.92%), BlackRock Inc. (1.28%), GSA Capital Partners LLP (0.79%), California Public Employees Retirement System (0.23%), Alps Advisors Inc. (0.13%) and Trexquant Investment LP (0.11%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Francis Fildes, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and BlackRock Inc.. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include Craig R Stapleton and Healthcare Master Fun Broadfin. View Insider Buying and Selling for Avadel Pharmaceuticals.

AVDL stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Trexquant Investment LP, O Shaughnessy Asset Management LLC, Alps Advisors Inc. and California Public Employees Retirement System. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $7.54.

Avadel Pharmaceuticals has a market capitalization of $274.12 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]